This is not the most recent version of the article. View current version (12 DEC 2012)

Intervention Protocol

Teriflunomide for multiple sclerosis

  1. Dian He1,
  2. Zhu Xu1,
  3. Hongyu Zhou2,*,
  4. Shihong Zhang2,
  5. Lu Wang2

Editorial Group: Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group

Published Online: 16 MAY 2012

Assessed as up-to-date: 13 JAN 2012

DOI: 10.1002/14651858.CD009882


How to Cite

He D, Xu Z, Zhou H, Zhang S, Wang L. Teriflunomide for multiple sclerosis (Protocol). Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No.: CD009882. DOI: 10.1002/14651858.CD009882.

Author Information

  1. 1

    Affiliated Hospital of Guiyang Medical College, Department of Neurology, Guiyang, Guizhou Province, China

  2. 2

    West China Hospital, Sichuan University, Department of Neurology, Chengdu, Sichuan, China

*Hongyu Zhou, Department of Neurology, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, 610041, China. Hyzhou98@yahoo.com.

Publication History

  1. Publication Status: New
  2. Published Online: 16 MAY 2012

SEARCH

This is not the most recent version of the article. View current version (12 DEC 2012)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To explore the potential benefits of teriflunomide and expand the available DMT options, the effectiveness and safety of teriflunomide as mono- and combination therapy, versus placebo or approved DMTs (IFN-β, glatiramer acetate, natalizumab, mitoxantrone, fingolimod or cladribine) for modifying disease in patients with MS will be assessed.